Diabetes, Vol 44, Issue 6 705-717, Copyright © 1995 by American Diabetes Association

ARTICLES

Lilly Lecture 1994. The beta-cell in diabetes: from molecular genetics to clinical research

KS Polonsky
Department of Medicine, University of Chicago, IL 60637, USA.

Pancreatic insulin secretion rates can be accurately derived by mathematical deconvolution of peripheral C-peptide concentrations either by using individual C-peptide kinetic parameters obtained by analysis of the decay curve of biosynthetic human C-peptide or by using published group parameters with appropriate adjustments for age and degree of obesity. Since the cross-reactivity of proinsulin and related peptides is low (< 10%) in many C-peptide assays, this experimental approach avoids the spurious increase in insulin immunoreactivity resulting from cross-reactivity with proinsulin and related peptides in the insulin assay. Application of this technique has demonstrated that the phenotypic expression of beta-cell dysfunction differs in subjects with different genetic mechanisms of non-insulin-dependent diabetes mellitus (NIDDM). Subjects who have maturity-onset diabetes of the young (MODY) due to mutations in the glucokinase gene demonstrate different patterns of altered insulin secretion when compared with subjects who have mutations in the MODY1 gene on chromosome 20. Glucokinase mutations affect the ability of the beta-cell to detect and respond to small increases in glucose above the basal level. However, compensatory mechanisms operative in vivo, which include a priming effect of glucose on insulin secretion, limit the severity of the observed insulin secretory defect, resulting in a generally mild clinical course in these subjects. In contrast, mutations in the MODY1 gene are associated with an inability to increase insulin secretion as the plasma glucose concentration increases above 7-8 mmol/l and the normal priming effect of glucose on insulin secretion is lost. These characteristics of the dose-response relationships between glucose and insulin secretion result in a more severe degree of hyperglycemia than observed in subjects with glucokinase mutations, and these subjects more frequently need insulin treatment. These alterations are evident in prediabetic subjects with normal glucose levels who carry the MODY1 mutation, suggesting that defective beta-cell function is the primary pathogenetic defect in the diabetic syndrome in these subjects. Studies performed in the classic form of NIDDM demonstrate that subjects with mild glucose intolerance and normal fasting glucose concentrations and glycosylated hemoglobin levels consistently demonstrate defective beta-cell function. These results are consistent with studies in the Zucker diabetic fatty rat, an animal model of NIDDM in which prediabetic animals demonstrate extensive alterations in expression of multiple genes involved in the regulation of insulin secretion. It thus appears that abnormal beta-cell function is present at a relatively early stage in the evolution of NIDDM, even before the onset of overt hyperglycemia.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J.-C. Henquin, D. Dufrane, and M. Nenquin Nutrient Control of Insulin Secretion in Isolated Normal Human Islets Diabetes, December 1, 2006; 55(12): 3470 - 3477. [Abstract] [Full Text] [PDF]

				M. D. Boudreau, H. W. Taylor, D. G. Baker, and J. C. Means Dietary Exposure to 2-Aminoanthracene Induces Morphological and Immunocytochemical Changes in Pancreatic Tissues of Fisher-344 Rats Toxicol. Sci., September 1, 2006; 93(1): 50 - 61. [Abstract] [Full Text] [PDF]

				S. V Joy, P. T Rodgers, and A. C Scates Incretin Mimetics as Emerging Treatments for Type 2 Diabetes Ann. Pharmacother., January 1, 2005; 39(1): 110 - 118. [Abstract] [Full Text] [PDF]

				M. Rosenbaum, C. Nonas, M. Horlick, I. Fennoy, I. Vargas, H. Schachner, P. Kringas, K. Stanton, R. Weil, and and the El Camino Diabetes Prevention Group {beta}-Cell Function and Insulin Sensitivity in Early Adolescence: Association with Body Fatness and Family History of Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5469 - 5476. [Abstract] [Full Text] [PDF]

				A. Caumo and L. Luzi First-phase insulin secretion: does it exist in real life? Considerations on shape and function Am J Physiol Endocrinol Metab, September 1, 2004; 287(3): E371 - E385. [Abstract] [Full Text] [PDF]

				K. Otani, R. N. Kulkarni, A. C. Baldwin, J. Krutzfeldt, K. Ueki, M. Stoffel, C. R. Kahn, and K. S. Polonsky Reduced {beta}-cell mass and altered glucose sensing impair insulin-secretory function in {beta}IRKO mice Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E41 - E49. [Abstract] [Full Text]

				A. Carpentier, B. Zinman, N. Leung, A. Giacca, A. J.G. Hanley, S. B. Harris, R. A. Hegele, and G. F. Lewis Free Fatty Acid-Mediated Impairment of Glucose-Stimulated Insulin Secretion in Nondiabetic Oji-Cree Individuals From the Sandy Lake Community of Ontario, Canada: A Population at Very High Risk for Developing Type 2 Diabetes Diabetes, June 1, 2003; 52(6): 1485 - 1495. [Abstract] [Full Text] [PDF]

				L. L. Kjems, J. J. Holst, A. Volund, and S. Madsbad The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion: Effects on {beta}-Cell Sensitivity in Type 2 and Nondiabetic Subjects Diabetes, February 1, 2003; 52(2): 380 - 386. [Abstract] [Full Text] [PDF]

				S. S. Fajans, G. I. Bell, and K. S. Polonsky Molecular Mechanisms and Clinical Pathophysiology of Maturity-Onset Diabetes of the Young N. Engl. J. Med., September 27, 2001; 345(13): 971 - 980. [Full Text] [PDF]

				V. Umpaichitra, W. Bastian, D. Taha, M. A. Banerji, T. W. AvRuskin, and S. Castells C-peptide and Glucagon Profiles in Minority Children with Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1605 - 1609. [Abstract] [Full Text]

				L. J. Bischof, C. C. Martin, C. A. Svitek, B. T. Stadelmaier, L. A. Hornbuckle, J. K. Goldman, J. K. Oeser, J. C. Hutton, and R. M. O’Brien Characterization of the Mouse Islet-Specific Glucose-6-Phosphatase Catalytic Subunit-Related Protein Gene Promoter by In Situ Footprinting: Correlation With Fusion Gene Expression in the Islet-Derived {beta}TC-3 and Hamster Insulinoma Tumor Cell Lines Diabetes, March 1, 2001; 50(3): 502 - 514. [Abstract] [Full Text]

				K. Minami, H. Yano, T. Miki, K. Nagashima, C.-Z. Wang, H. Tanaka, J.-I. Miyazaki, and S. Seino Insulin secretion and differential gene expression in glucose-responsive and -unresponsive MIN6 sublines Am J Physiol Endocrinol Metab, October 1, 2000; 279(4): E773 - E781. [Abstract] [Full Text] [PDF]

				L. Segall, N. Lameloise, F. Assimacopoulos-Jeannet, E. Roche, P. Corkey, S. Thumelin, B. E. Corkey, and M. Prentki Lipid rather than glucose metabolism is implicated in altered insulin secretion caused by oleate in INS-1 cells Am J Physiol Endocrinol Metab, September 1, 1999; 277(3): E521 - E528. [Abstract] [Full Text] [PDF]

				R. A. DeFronzo Pharmacologic Therapy for Type 2 Diabetes Mellitus Ann Intern Med, August 17, 1999; 131(4): 281 - 303. [Abstract] [Full Text] [PDF]

				A. Carpentier, S. D. Mittelman, R. N. Bergman, A. Giacca, and G. F. Lewis Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation Am J Physiol Endocrinol Metab, June 1, 1999; 276(6): E1055 - E1066. [Abstract] [Full Text] [PDF]

				C. A. Aspinwall, J. R. T. Lakey, and R. T. Kennedy Insulin-stimulated Insulin Secretion in Single Pancreatic Beta Cells J. Biol. Chem., March 5, 1999; 274(10): 6360 - 6365. [Abstract] [Full Text] [PDF]

				S. Jitrapakdee, Q. Gong, M. J. MacDonald, and J. C. Wallace Regulation of Rat Pyruvate Carboxylase Gene Expression by Alternate Promoters during Development, in Genetically Obese Rats and in Insulin-secreting Cells. MULTIPLE TRANSCRIPTS WITH 5'-END HETEROGENEITY MODULATE TRANSLATION J. Biol. Chem., December 18, 1998; 273(51): 34422 - 34428. [Abstract] [Full Text] [PDF]

				S. A. Urhammer, T. Hansen, C. T. Ekstrøm, H. Eiberg, and O. Pedersen The Ala/Val98 Polymorphism of the Hepatocyte Nuclear Factor-1{alpha} Gene Contributes to the Interindividual Variation in Serum C-Peptide Response during an Oral Glucose Tolerance Test: Evidence from Studies of 231 Glucose-Tolerant First Degree Relatives of Type 2 Diabetic Probands J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4506 - 4509. [Abstract] [Full Text]

				E. Ferrannini Insulin Resistance versus Insulin Deficiency in Non-Insulin-Dependent Diabetes Mellitus: Problems and Prospects Endocr. Rev., August 1, 1998; 19(4): 477 - 490. [Abstract] [Full Text] [PDF]

				Y.-H. Lee, B. Sauer, and F. J. Gonzalez Laron Dwarfism and Non-Insulin-Dependent Diabetes Mellitus in the Hnf-1alpha Knockout Mouse Mol. Cell. Biol., May 1, 1998; 18(5): 3059 - 3068. [Abstract] [Full Text]

				E. A. Cabanas Maturity-Onset Diabetes of the Young: Recent Findings Indicate Insulin Resistance/Obesity Are Not Factors The Diabetes Educator, January 1, 1998; 24(4): 477 - 480. [PDF]

				C. B. Verchere, M. Paoletta, M. Neerman-Arbez, K. Rose, J.-C. Irminger, R. L. Gingerich, S. E. Kahn, and P. A. Halban Des-(, , , , )C-Peptide. A NOVEL SECRETORY PRODUCT OF THE RAT PANCREATIC BETA CELL PRODUCED BY TRUNCATION OF PROINSULIN CONNECTING PEPTIDE IN SECRETORY GRANULES J. Biol. Chem., November 1, 1996; 271(44): 27475 - 27481. [Abstract] [Full Text] [PDF]

				K. S. Polonsky, J. Sturis, and G. I. Bell Non-Insulin-Dependent Diabetes Mellitus -- A Genetically Programmed Failure of the Beta Cell to Compensate for Insulin Resistance N. Engl. J. Med., March 21, 1996; 334(12): 777 - 783. [Full Text] [PDF]

				Z. Gao, J. Reavey-Cantwell, R. A. Young, P. Jegier, and B. A. Wolf Synaptotagmin III/VII Isoforms Mediate Ca2+-induced Insulin Secretion in Pancreatic Islet beta -Cells J. Biol. Chem., November 10, 2000; 275(46): 36079 - 36085. [Abstract] [Full Text] [PDF]